Toggle light / dark theme

NASA has selected SpaceX of Hawthorne, California, to provide launch services for the agency’s Psyche mission. The Psyche mission currently is targeted to launch in July 2022 on a Falcon Heavy rocket from Launch Complex 39A at Cape Canaveral Air Force Station in Florida.

The total cost for NASA to launch Psyche and the secondary payloads is approximately $117 million, which includes the launch service and other mission related costs.

The Psyche mission will journey to a unique metal-rich asteroid, also named Psyche, which orbits the Sun between Mars and Jupiter. The asteroid is considered unique, as it appears to largely be made of the exposed nickel-iron core of an early planet – one of the building blocks of our solar system.

Music therapy can help improve brain and motor function in stroke patients, scientists say.

A new study has found taking part in music sessions can boost mood and improve concentration in patients recovering from stroke. Those participating in the two-year sessions alongside existing stroke rehabilitation treatment also reported physical benefits such as better arm function and gait.

Based on their trials, the researchers are preparing a proposal for an NHS-funded permanent music therapy sessions post on the stroke ward at the Addenbrooke’s hospital in Cambridge, where the study was conducted.

China has said that some vaccines for the novel coronavirus could be in clinical use next month as the number of global coronavirus cases soared past 100,000.

The country’s scientists are striving to develop immunisation products with five technologies simultaneously, according to officials.

‘We estimate that in April — in line with country’s relevant law and regulations – there is hope that some of the vaccines can enter the stage of clinical or emergency use,’ said Zheng Zhongwei, director of the Technical Development and Research Centre of China’s National Health Commission.

Immunotherapy is an increasingly powerful form of cancer treatment where the patient’s own immune system is equipped with heightened abilities to take down the disease, and one promising arm of this is known as adoptive cell therapy. This involves using altered versions of a patient’s own cells to trigger a more strong-handed response from their own immune system. Scientists at Johns Hopkins Kimmel Cancer Center are reporting an exciting advance in this area, demonstrating that engineered bone marrow cells can slow the growth of prostate and pancreatic cancers in mice.

The study builds on previous research where scientists demonstrated that a range of cancers, including melanomas, colon cancer and brain cancer, grow much more slowly in mice that are lacking a certain gene, known as p50, which seems to activate a stronger immune response. The Johns Hopkins researchers sought to further validate these earlier findings, while expanding the utility of a promising form of cancer therapy.

To do this, the team worked with what are known as immature myeloid cells, a type of white blood cell, which previous research had indicated could help switch on immune responses that fight tumors. In this case, the immature myeloid cells were taken from the bone marrow of mice engineered to lack the p50 gene, as a way of comparing them to the behavior of cells taken from mice who had the p50 gene in tact.